uniQure (QURE)
(Real Time Quote from BATS)
$8.88 USD
+0.16 (1.84%)
Updated Jul 15, 2024 10:06 AM ET
2-Buy of 5 2
D Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
QURE 8.88 +0.16(1.84%)
Will QURE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for QURE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for QURE
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet
QURE: What are Zacks experts saying now?
Zacks Private Portfolio Services
uniQure (QURE) Soars on New Huntington's Disease Study Data
uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?
Down -29.74% in 4 Weeks, Here's Why You Should You Buy the Dip in uniQure (QURE)
Other News for QURE
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
uniQure Shareholders Approve Board and Financial Decisions
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
uniQure’s Gene Therapy Earns FDA Advanced Therapy Designation
uniQure receives RMAT designation of AMT-130 in Huntington's Disease